Morepen Laboratories Ltd. Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2017
January 21, 2018 at 11:36 pm EST
Share
Morepen Laboratories Ltd. reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2017. For the quarter, the company reported total revenue of INR 1,427.363 million compared to INR 1,390.488 million a year ago. Profit before exceptional item and tax was INR 96.711 million compared to INR 46.797 million a year ago. Profit before tax was INR 96.711 million compared to INR 46.797 million a year ago. Net profit for the period was INR 96.711 million compared to INR 46.797 million a year ago. Earnings of INR 0.21 per basic and diluted share compared to INR 0.09 per basic and diluted share a year ago. EBITDA grew by over 18% at INR 181.7 million compared to INR 153.4 million a year ago. Cash profit during the period rose by 32% at INR 172.7 million compared to INR 131.1 million a year ago. Net sales revenue was INR 1,398.7 million compared to INR 1,372.7 million a year ago. Expenditure was INR 1,245.7 million compared to INR 1,237.1 million a year ago.
For the nine months, the company reported total revenue of INR 4,060.288 million compared to INR 4,036.294 million a year ago. Profit before exceptional item and tax was INR 220.084 million compared to INR 159.954 million a year ago. Profit before tax was INR 220.084 million compared to INR 159.954 million a year ago. Net profit for the period was INR 220.084 million compared to INR 159.954 million a year ago. Earnings of INR 0.48 per basic and diluted share compared to INR 0.34 per basic and diluted share a year ago. EBITDA was at INR 491.4 million compared to INR 474.8 million a year ago. Cash surplus was INR 456.4 million compared to INR 411.6 million a year ago. Net sales revenue was INR 3,968.7 million compared to INR 3,970.9 million a year ago. Expenditure was INR 3,568.9 million compared to INR 3,561.5 million a year ago.
Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Febuxostat, Montelukast (Oral), Montelukast (Chewable), among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen 49W Room Air Purifier with HEPA Filter, Dr. Morepen VP06 Breathe Free Vaporizer, Dr. Morepen CN06 Compressor Nebulizer and Dr. Morepen ST03 Dual Head Stethoscope, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.